ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

PerkinElmer Launches BioQule NGS System to Automate Library Preparation

Affordable, easy-to-use benchtop system empowers labs of all sizes to both generate and quality control NGS libraries for genomic analysis

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced the launch of the research use only (RUO) BioQule™ NGS System – an automated benchtop solution for next-generation sequencing (NGS) library preparation of up to eight samples. By incorporating automated thermocycling, integrated quality control through optical quantification and robust liquid handling technology into a single device, the BioQule NGS System enables researchers to produce high quality NGS libraries that yield reliable, reproducible results in a variety of applications requiring genomic analysis.

Unlike existing solutions for NGS library preparation, which are expensive and rely on external solutions to perform concentration measurements on their libraries, the BioQule NGS System provides in-built quantification of NGS libraries it creates. Methods and kits used with the BioQule NGS System are predeveloped and pre-verified, and the entire system can be installed, set-up and run by the user without any specialized vendor support.

“Library preparation for NGS is a critical, yet complex and often error-prone process that can be optimized with automation, both in terms of yield and cost benefits,” said PerkinElmer SVP of Diagnostics Yves Dubaquie. “The BioQule NGS System is an ideal solution for any lab performing NGS library preparation, including small and mid-sized labs pursuing research in genomics and transcriptomics, or large reference laboratories. The BioQule NGS System can be customized to a given lab’s workflow requirements and requires no prior automation experience to use.”

In addition to its simple design and walk-away automation capabilities, the BioQule NGS System expands opportunities in NGS library preparation by requiring as little as 10 ng of starting material to create libraries, while others require 50 ng or more. PerkinElmer currently offers two DNA library prep kits that are automated on the system – the NEXTFLEX® Rapid XP DNA-Seq Kit and the NEXTFLEX® Rapid DNA-Seq Kit 2.0. Additional library prep kits compatible with BioQule NGS System are currently in development.

The BioQule NGS System will be on display at PerkinElmer’s booth (located in the Fulton suite) at the Advances in Genome Biology and Technology (AGBT) General Meeting from June 6-9, 2022 in Orlando, Florida.

To learn more about the BioQule NGS System and PerkinElmer’s end-to-end automated genomics workflows, visit this webpage.

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.